argenx (ARGX) Stock Forecast & Price Target

argenx is on track to have a strong financial year, with two FDA approvals already achieved and potential approval for a third indication in the pipeline. Sales of Vyvgart have shown strong growth, driven by the success of the subcutaneous formulation and expansion into new indications. The company's pipeline is also promising, with multiple first-in-class molecules expected to enter Phase 1 studies in 2026 and potential for significant growth in the IMNM, DM, and PM markets. With an OUTPERFORM rating and a PT of $1000, analysts are optimistic about the company's outlook and potential for continued success.

argenx is a well-established biopharmaceutical company that has a strong focus on innovation and developing its pipeline for rare autoimmune diseases. However, the company faces several risks that could impact growth, including competition, potential adverse events in clinical trials, and macroeconomic factors. While the company has seen success with the FDA approvals for Vyvgart, a convenient subcutaneous formulation, and potential label expansions, the ultimate success of these developments remains to be seen. Furthermore, while management has highlighted strong financials and plans for margin expansion, there remains the risk of further investment in R&D and business development that could impact profitability.